Effect of angiotensin II type 2 receptor on stroke, cognitive impairment and neurodegenerative diseases.
Here, we briefly review the role of the renin-angiotensin system (RAS) in cognitive impairment and neurodegenerative disease, mainly discussing our experimental studies on the angiotensin II type 2 (AT(2)) receptor. Ischemic brain damage is enhanced in mice with overexpression of angiotensin II, with reduced cerebral blood flow in the penumbra and an increase in oxidative stress in the ischemic area. Angiotensin II binds two types of receptors, type 1 (AT(1)) and type 2 (AT(2)). Our previous experiments showed that AT(1) receptor signaling has a harmful effect, and AT(2) receptor signaling has a protective effect on the brain after stroke. AT(2) receptor signaling in bone marrow stromal cells or hematopoietic cells was shown to prevent ischemic brain damage after middle cerebral artery occlusion. In contrast, AT(2) receptor signaling also affects cognitive function. We showed that direct stimulation of the AT(2) receptor by a newly generated direct AT(2) receptor agonist, Compound 21 (C21), enhanced cognitive function in wild-type (C57BL6) mice and an Alzheimer's disease mouse model with intracerebroventricular injection of amyloid β (1-40). Finally, we carried out clinical research by investigating the levels of RAS components in patients with neurodegenerative diseases. We observed a reduction of angiotensin II and angiotensin converting enzyme (ACE) 2 levels, and an increase in ACE level in cerebrospinal fluid from patients with multiple sclerosis. These results suggest that RAS is also involved in neurodegenerative disease. Therefore, regulation of RAS might be a new therapeutic target to protect neurons from neural diseases.
Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University Graduate School of Medicine, Ehime, Japan. mmogi@m.ehime-u.ac.jp
Masaki
M
Mogi
Masatsugu
M
Horiuchi
D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D000818:Animals; D001923:Brain Chemistry / Q000502:physiology; D002454:Cell Differentiation; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D003072:Cognition Disorders / Q000188:drug therapy* / Q000503:physiopathology*; D006801:Humans; D051379:Mice; D019636:Neurodegenerative Diseases / Q000188:drug therapy* / Q000503:physiopathology*; D007703:Peptidyl-Dipeptidase A / Q000502:physiology; D044139:Receptor, Angiotensin, Type 2 / Q000819:agonists / Q000502:physiology*; D012084:Renin-Angiotensin System / Q000502:physiology*; D015398:Signal Transduction; D020521:Stroke / Q000188:drug therapy* / Q000503:physiopathology*
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D044139:Receptor, Angiotensin, Type 2; D007703:Peptidyl-Dipeptidase A